Truvada and Tenofovir (TDF) lawsuits: where the Gilead HIV drug litigation actually stands as bellwethers approach

The Gilead Sciences tenofovir disoproxil fumarate (TDF) litigation represents one of the largest pharmaceutical mass torts currently pending without formal MDL consolidation. Approximately 25,000 to 26,000 plaintiffs are pending across two distinct procedural frameworks: an "organic" MDL in the U.S. District Court for the Northern District of California (where Gilead is headquartered) before Judge Jon S. Tigar, and the California state court coordinated proceeding (Judicial Council Coordination Proceeding No. 5043, "Gilead Tenofovir Cases and Coordinated Actions") in San Francisco Superior Court. The plaintiffs allege that Gilead's TDF-based HIV drugs — including Viread, Truvada, Atripla, Complera, and Stribild — caused kidney damage and bone density loss, and that Gilead knew about these risks as early as 2001 but withheld a safer alternative drug (tenofovir alafenamide, or TAF) to maximize profits from TDF-based medications before patents expired.

The substantive theory has two integrated components. First, the failure-to-warn claim: Gilead allegedly knew TDF drugs caused substantial kidney and bone toxicity but didn't adequately warn patients or healthcare providers. The FDA reprimanded Gilead in 2002 and 2003 for false claims about TDF safety, supporting plaintiffs' theory that Gilead had material knowledge of risks. Second, the alternative drug theory: Gilead allegedly developed TAF (a safer formulation) around 2004 but shelved the research, releasing TAF only when TDF patents were nearing expiration. Plaintiffs argue Gilead strategically delayed TAF to extend its TDF monopoly and maximize profits before generic TDF could enter the market. The California Supreme Court is currently reviewing whether plaintiffs must prove TDF itself was defective or whether evidence of withholding a safer alternative is sufficient under California product liability law — a ruling that will substantially affect the litigation's future.

The settlement landscape has been challenging for plaintiffs. In June 2024, Gilead announced a $40 million settlement for approximately 2,625 federal MDL plaintiffs — averaging just $12,500 per plaintiff. Many plaintiffs and their attorneys characterized the offer as substantially inadequate given the severity of injuries (kidney failure, dialysis, bone fractures, osteomalacia). The federal settlement required 98% opt-in to take effect. Meanwhile, the much larger California state court litigation involving over 24,000 plaintiffs continues without comprehensive global settlement. Bellwether trials in California state court were scheduled for late 2025 and early 2026 to help guide future settlement negotiations. The federal MDL bellwether trial originally planned for November 2024 was delayed pending settlement discussions and the California Supreme Court review.

This is the science behind the TDF kidney and bone toxicity theory, the procedural history through the current bellwether and California Supreme Court phase, the eligibility framework for current and prospective plaintiffs, the substantial settlement and litigation strategy considerations, and the implications of the pending California Supreme Court ruling for the broader litigation framework.

What TDF is and the alleged defect

TDF is a critical component of HIV antiretroviral therapy:

TDF mechanism. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor (NRTI) that blocks HIV's ability to replicate. The active compound (tenofovir) prevents HIV from using the reverse transcriptase enzyme needed for viral replication. TDF was the first oral form of tenofovir, approved by FDA in 2001. Before TDF, tenofovir required injection administration that limited clinical utility.

TDF metabolism issue. Once absorbed, TDF accumulates in kidney tubule cells at concentrations substantially higher than in blood plasma. The accumulation causes direct toxicity to renal tubular cells, leading to various forms of kidney damage. Similar mechanisms affect bone health through phosphate wasting and disrupted bone mineralization.

Gilead's TDF drugs covered in the litigation:

Viread (tenofovir disoproxil fumarate alone)
Truvada (TDF + emtricitabine — most prescribed)
Atripla (TDF + emtricitabine + efavirenz)
Complera (TDF + emtricitabine + rilpivirine)
Stribild (TDF + emtricitabine + elvitegravir + cobicistat)
Symfi Lo, Symfi (various TDF combinations)

All these drugs share the TDF component and the underlying toxicity issue.

TAF alternative. Tenofovir alafenamide (TAF) is a newer formulation of tenofovir that:

Requires lower doses to be effective
Accumulates less in kidney and bone tissue
Has similar HIV efficacy to TDF
Has substantially reduced kidney and bone toxicity

Gilead introduced TAF-based medications (Descovy, Genvoya, Odefsey) starting around 2015-2016. The TAF patent expires around 2032, providing Gilead substantial additional monopoly period beyond TDF.

The strategic delay theory. Plaintiffs allege Gilead:

Knew TDF caused kidney and bone damage from 2001
Developed TAF around 2004 as a safer alternative
Shelved TAF research to maximize TDF profits during TDF's patent period
Released TAF only when TDF patents were nearing expiration (around 2015)
Encouraged doctors to switch patients to TAF when generic TDF was about to enter the market
This pattern extended Gilead's monopoly on tenofovir-based HIV medications

Internal corporate knowledge. Discovery has produced internal Gilead documents about TDF risks and TAF development. The FDA's 2002 and 2003 reprimands for false safety claims provide substantial supporting evidence for plaintiffs' theory that Gilead had information about TDF risks that wasn't adequately disclosed.

The alleged injuries

Plaintiffs allege various kidney and bone injuries from TDF use:

Kidney injuries:

Acute kidney injury (AKI) — sudden loss of kidney function, sometimes requiring temporary dialysis
Chronic kidney disease (CKD) — progressive kidney function decline
End-stage renal disease (ESRD) — requiring permanent dialysis or kidney transplant
Fanconi syndrome — kidney tubule damage causing phosphate wasting, protein loss in urine, and metabolic acidosis
Renal tubular acidosis — kidney's inability to acidify urine properly

Bone injuries:

Osteoporosis — bone density loss
Osteomalacia — softening of bones due to vitamin D and phosphate metabolism problems
Bone fractures — particularly hip, vertebral, and stress fractures
Decreased bone mineral density (BMD) — measurable through DEXA scans

Lab markers supporting causation:

Elevated serum creatinine
Declining estimated glomerular filtration rate (eGFR)
Proteinuria (protein in urine)
Low phosphate levels (hypophosphatemia)
Phosphaturia (phosphate wasting in urine)
Glycosuria without diabetes

Severity range. Injuries range from manageable kidney function changes to:

Permanent kidney failure requiring lifelong dialysis
Kidney transplant requirement
Catastrophic bone fractures requiring surgery
Multiple hip replacements
Permanent disability and reduced quality of life

The injury severity affects compensation valuation substantially. Some plaintiffs have undergone multiple hip replacements, complete tooth loss from osteomalacia, and ongoing dialysis with poor quality of life.

The procedural history

The litigation has developed through unusual procedural pathways:

2001-2018. TDF drugs in widespread clinical use. Adverse effects gradually documented in medical literature. Some early lawsuits filed but not consolidated.

February 2018. AIDS Healthcare Foundation (AHF) filed class action lawsuit on behalf of patients who purchased TDF drugs. Substantial public attention to the litigation.

February 2019. Plaintiffs withdrew motion for formal MDL (would have been MDL 2881 — In Re: Tenofovir Disoproxil Fumarate Products Liability Litigation). The withdrawal left the litigation without formal federal MDL consolidation.

April 2019. Northern District of California began consolidating federal TDF cases before Judge Jon S. Tigar for pretrial purposes. The consolidation created an "organic" or informal MDL through case transfers rather than JPML order.

August 2019. California state court coordinated proceeding established — Judge Kenneth R. Freeman ordered all California state TDF lawsuits coordinated before single judge in San Francisco Superior Court. Designated as Judicial Council Coordination Proceeding No. 5043 ("Gilead Tenofovir Cases and Coordinated Actions").

Throughout 2020-2023. Active discovery in both federal MDL and California state coordinated proceeding. Substantial document production from Gilead. Expert testimony developed.

November 2023. Judge Tigar denied Gilead's motion to dismiss design defect and failure-to-warn claims in federal MDL, preserving plaintiffs' substantive theories.

2023-2024. Federal MDL motion practice continued. Daubert challenges to expert testimony filed. Judge Tigar tossed out eight of Gilead's experts after concluding their opinions were largely identical and probably ghostwritten by Gilead's lawyers.

June 2024. GILEAD SETTLEMENT OFFER. Gilead announced agreement in principle to pay $40 million to settle 2,625 federal MDL cases. Averaging approximately $12,500 per plaintiff. The settlement required 98% opt-in to take effect.

Late 2024-Early 2025. Settlement administration for federal MDL cases. California state court litigation continued without comprehensive settlement. Federal bellwether trial originally planned November 2024 stayed pending settlement.

2024-2025. CALIFORNIA SUPREME COURT REVIEW. The California Supreme Court agreed to review key issue: whether plaintiffs must prove TDF itself was defective or whether evidence of withholding safer alternative TAF is sufficient under California product liability law.

2025-2026 California Supreme Court briefing. Plaintiffs' response due November 2025. Gilead's reply expected January 2026. Oral argument likely first half of 2026. Decision typically issued within 90 days after oral argument.

Late 2025-Early 2026 California state court bellwethers. Bellwether trials scheduled in California state court to test key issues and help guide future settlements.

Mid-2026 federal bellwethers. Federal MDL bellwether trials scheduled (specific dates subject to ongoing developments).

Current status. The litigation is in an unusual procedural posture awaiting:

California Supreme Court ruling on liability standards
California state court bellwether outcomes
Federal MDL bellwether outcomes
Resolution of remaining ~22,000+ plaintiffs not covered by $40 million federal settlement

The California Supreme Court question

The pending California Supreme Court review addresses a fundamental product liability question:

The legal issue. Whether plaintiffs in product liability cases involving allegedly safer alternative drugs must:

Prove the original drug was defectively designed under traditional product liability standards, OR
Show that the manufacturer withheld a safer alternative drug for non-medical reasons (commercial advantage)

Why this matters. The standard substantially affects the litigation:

Under traditional defective design standard. Plaintiffs would need to prove TDF itself was defectively designed compared to existing alternatives at the time of marketing. Given TDF was substantially safer and more effective than prior HIV medications, this could be difficult.

Under the "safer alternative" theory. Plaintiffs would need to show Gilead had a safer alternative (TAF) available but withheld it. This is substantially easier to prove given the documented TAF development history.

Industry-wide implications. The ruling could affect:

All pharmaceutical product liability litigation in California
Litigation involving generic alternatives, follow-on drugs, and similar situations
Investment and development incentives for safer drug formulations
Industry strategy on drug release timing relative to patent protection

Expected ruling timeline. Oral argument first half of 2026, decision within 90 days after argument. Ruling likely mid-to-late 2026.

The California Supreme Court ruling will substantially affect both pending Gilead litigation and future pharmaceutical product liability cases in California. Industry-wide attention to the case reflects its precedential significance beyond the specific Gilead facts.

Eligibility framework

The framework for filing TDF-related claims:

Documented TDF medication use. Records showing the claimant took one of the Gilead TDF drugs:

Prescription records
Pharmacy fill records
Medical chart references
Insurance prescription benefit records

Qualifying injury. Documented kidney or bone injury including:

Acute or chronic kidney disease
End-stage renal disease
Fanconi syndrome
Osteoporosis or osteomalacia
Bone fractures
Other TDF-related complications

Temporal relationship. The injury developed during or after TDF use. Long-term users (typically 1+ years on TDF) have stronger cases than short-term users.

Documentation requirements:

Medical records showing TDF prescription history
Lab results documenting kidney function decline (serum creatinine, eGFR, urinalysis)
DEXA scan results showing bone density loss
Fracture records and orthopedic evaluations
Dialysis records (if applicable)
Treatment records for related complications
Lost wages documentation
Quality of life impact documentation

Statute of limitations analysis. Most states have 2-4 year limitations periods. California has 2-year limitations for personal injury under Cal. Civ. Proc. §335.1. The discovery rule applies — limitations begins when plaintiff knew or should have known about TDF's causal connection to the injury. Many plaintiffs only became aware of the TDF connection through litigation publicity, supporting discovery rule extension.

Federal vs. state court analysis. Plaintiffs may file in:

Federal MDL (N.D. Cal.) — for federal jurisdiction cases. Recent federal settlement may affect new filings.
California state coordinated proceeding (JCCP 5043) — for California residents or California-related cases
Other state courts — for plaintiffs in other states (some plaintiffs in Missouri, Delaware, Florida, New York)

The choice of forum affects procedural timeline and potential outcomes. California state court has produced more favorable rulings for plaintiffs than federal MDL in some procedural matters.

Settlement projections

Settlement valuation is complex given the unusual procedural posture:

Federal MDL settlement (2024). $40 million for 2,625 plaintiffs averaged $12,500 per plaintiff. The amount was widely criticized as substantially inadequate given injury severity.

Future settlement framework. Likely depends on:

California Supreme Court ruling on liability standard
California state court bellwether outcomes
Federal MDL bellwether outcomes if not stayed
Gilead's ongoing financial capacity (substantial — annual TDF revenues exceeded $11 billion)

Injury severity tiers. Eventual settlement likely structured by injury tiers:

Tier 1: Permanent kidney failure / ESRD requiring dialysis or transplant. Typical settlement range: $300,000-$2,000,000+ depending on age, medical costs, lost wages, quality of life impact.

Tier 2: Substantial chronic kidney disease without complete failure. Typical settlement range: $100,000-$500,000.

Tier 3: Major bone injuries (hip fractures, multiple fractures, hip replacements). Typical settlement range: $75,000-$400,000.

Tier 4: Documented but less severe kidney/bone injuries. Typical settlement range: $25,000-$100,000.

Tier 5: Documented kidney function decline without major complications. Typical settlement range: $10,000-$50,000.

Tax implications. Personal injury settlements for physical injuries are generally tax-free under IRC §104(a)(2). Settlement allocation between physical injury (tax-free) and other components (potentially taxable) requires careful structuring. When plaintiffs face other tax issues, coordination with tax debt forgiveness procedures and NFTL withdrawal may be relevant to overall financial planning.

Gilead's financial capacity. Gilead generates substantial annual revenues (over $25 billion in 2024) with strong financial position. The company can fund substantial settlements without bankruptcy considerations affecting the litigation.

How TDF litigation compares to other mass torts

The litigation has distinctive features:

Compared to Roundup litigation with $11+ billion in settlements: Both involve substantial corporate financial capacity for settlement. Roundup reached comprehensive settlement; TDF is in earlier resolution phase.

Compared to Zantac NDMA MDL facing similar product liability theories: Both involve pharmaceutical product liability with internal corporate knowledge issues. Zantac federal MDL was dismissed; state court litigation continues. TDF has substantial state court activity and ongoing federal litigation.

Compared to Ozempic GLP-1 MDL 3094 in earlier procedural phase: TDF is procedurally further along with bellwethers approaching but unusual non-MDL framework.

Compared to Tylenol autism MDL facing Daubert challenges: Both face substantial scientific causation issues. TDF has stronger documented internal corporate knowledge.

Compared to Hair relaxer cancer MDL with growing case count: Both have substantial scientific basis. Hair relaxer is earlier in procedural development.

Compared to Bard PowerPort MDL 3081 with bellwethers beginning: Both have active bellwether activity. PowerPort has formal MDL; TDF has organic MDL plus state coordinated proceeding.

Distinctive TDF features:

No formal MDL (motion withdrawn 2019) — organic consolidation only
Large California state coordinated proceeding (24,000+ plaintiffs)
California Supreme Court reviewing key liability standard
$40 million federal settlement covering only ~10% of plaintiffs
Substantial documented internal corporate knowledge of risks
FDA reprimands supporting plaintiffs' theory
Long-term clinical use providing extensive injury documentation
Cancer patient analog: many plaintiffs needed HIV medications for life-saving treatment

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. TDF represents one of the largest pharmaceutical mass torts pending without formal MDL consolidation.

Strategic considerations

For prospective plaintiffs and those evaluating the litigation:

Engage experienced mass tort counsel immediately. The litigation is procedurally complex with multiple parallel tracks (federal organic MDL, California state coordinated proceeding, other state filings). Counsel with established TDF case experience handles these cases substantially better than general practitioners.

Document medication history comprehensively. The strongest cases include:

Prescription records for all TDF medications used
Duration of use for each medication
Dosage and treatment history
Concurrent medications
Healthcare provider documentation
Insurance prescription benefit records

Document injury timeline carefully. Establish the timeline of:

TDF medication start dates
First symptoms of kidney or bone injuries
Initial diagnosis dates
Treatment escalation
Major complications (dialysis, transplant, fractures)
Current status

Lab evidence is critical. Comprehensive lab documentation strengthens cases substantially:

Serum creatinine trends over time
eGFR decline patterns
Urinalysis showing proteinuria, glycosuria
Phosphate levels
DEXA bone density scans
Fracture imaging

Coordinate with treating physicians. Nephrologists, endocrinologists, primary care physicians, and infectious disease specialists are important witnesses. Their support for the case theory strengthens cases.

Watch the California Supreme Court ruling carefully. The pending decision on liability standards will substantially affect:

Strength of remaining cases
Settlement valuation
Strategic options for individual cases

Plan for multiple scenarios depending on the ruling.

Consider venue carefully. Choice between federal MDL participation and state court filing depends on:

State of residence
Treatment locations
Strength of specific case
Statute of limitations considerations
Procedural strategy

Don't accept inadequate pre-bellwether settlements. The $40 million federal settlement averaged $12,500/plaintiff — substantially inadequate for serious injuries. Larger state court litigation expects substantially higher per-plaintiff valuations following bellwether outcomes.

Plan for extended timeline. California Supreme Court ruling expected late 2026. Bellwether outcomes in 2026-2027. Global settlement (if reached) likely 2027-2029. Plan financially for extended timeline.

Address related tax considerations. Personal injury settlements for physical injuries are tax-free under §104(a)(2). Coordinate with tax counsel for substantial settlements. If facing other tax issues, integrate with Voluntary Disclosure Practice considerations where appropriate.

Watch for wrongful death claims. Some TDF plaintiffs have died from kidney failure or related complications. Estates can pursue wrongful death claims with separate procedural framework. Family members may be eligible for compensation beyond the decedent's own claim.

Maintain current HIV treatment. TDF litigation shouldn't interfere with current HIV treatment. Most plaintiffs have already been switched to TAF-based medications by their healthcare providers. Maintain medication compliance for HIV management regardless of litigation status.

Consider University of Arizona Law expungement clinic analog for case assistance. Some law schools and legal aid organizations provide assistance for TDF cases. Resources may be available beyond traditional plaintiffs' firms.

Plan for the litigation's continuing development. New legal developments may substantially affect strategy:

Bellwether outcomes
California Supreme Court ruling
Daubert ruling appeals
Settlement negotiation developments

Stay informed through counsel updates.

The Gilead TDF litigation represents one of the most consequential pharmaceutical mass torts currently pending, with approximately 25,000+ plaintiffs across federal and state procedural frameworks. The substantive theory — that Gilead knew TDF caused kidney and bone damage and withheld safer TAF alternative for commercial advantage — has substantial documented support including FDA reprimands and internal corporate documents. The procedural posture is unusual (no formal MDL, large state coordinated proceeding, pending California Supreme Court review on liability standards), but the litigation is procedurally mature enough that meaningful resolution should follow bellwether outcomes and the California Supreme Court ruling. For plaintiffs with documented TDF use and substantial kidney or bone injuries, the framework provides paths to compensation that should produce meaningful outcomes once the procedural complications resolve. The $40 million federal settlement's low per-plaintiff value ($12,500 average) substantially understates likely valuations for severe injury cases — those settlements were procedural compromises rather than market valuations of the underlying claims. Plaintiffs with strong documented cases should expect substantially higher valuations through state court litigation and post-bellwether settlements. The work for plaintiffs is in comprehensive documentation, engagement with experienced counsel familiar with both federal MDL and California state coordinated proceeding frameworks, patience with the extended procedural timeline, and informed monitoring of the California Supreme Court review and bellwether developments that will substantially shape the litigation's resolution framework.